Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the 11 most profitable NASDAQ stocks to buy now. On June 9, Regeneron ...

These are the first clinical study results for the drug in a large population of patients with darker skin tones ...

Regeneron and Sanofi have announced promising outcomes from the open-label Phase IV DISCOVER trial of Dupixent (dupilumab).

Compared with other systemic agents for treating atopic dermatitis, dupilumab is associated with an increased risk for ...

Regeneron Pharmaceuticals Inc. (NASDAQ ... in treating moderate-to-severe atopic dermatitis/AD in adolescents and adults with skin of color. These findings were presented at the 2025 ...

Atopic dermatitis manifests differently in patients with darker skin color, according to the companies, including subtler ...

Paris: Sanofi has announced that results from the DISCOVER phase 4, single-arm, open-label study assessing Dupixent ...

PORTLAND, OR, UNITED STATES, June 18, 2025 /EINPresswire.com/ -- The global atopic dermatitis market is witnessing unprecedented growth, projected to expand from $5.3 billion in 2021 to $22.6 billion ...

Since their introduction with Sanofi/Regeneron’s Dupixent ... Additionally, 23.6% of patients achieved a validated Investigator’s Global Assessment for Atopic Dermatitis score of 0-1 with at least a ...

The American Academy of Dermatology gratefully acknowledges the support from Sanofi and Regeneron. Atopic dermatitis, or eczema, is often called the “itch that rashes.” This description explains what ...